MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company’s director of business development, Matthew Vincent, Ph.D., will be presenting at the 2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum, Nov. 30 to Dec. 1 in La Jolla, California.
In his presentation, Dr. Vincent will provide an overview of ACT’s ocular programs. The presentation will be webcast by the Alliance for Regenerative Medicine starting on Friday, December 2.
The following are specific details regarding ACT’s presentation at the conference:
2011 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum
|Date:||November 30, 2011|
|Time:||11 a.m. PST|
|Location:||Sanford Consortium for Regenerative Medicine Building|
|10010 North Torrey Pines Road, La Jolla, California|
About the Stem Cell Meeting on the Mesa’s Investor and Partnering Forum
The Investor and Partnering Forum is being organized by the Sanford Consortium, CIRM and The Alliance for Regenerative Medicine (ARM) to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings. To learn more or to register for the 2011 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit www.stemcellmeetingonthemesa.com.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
James Young, 212-732-4300
ACT Corporate Communications
Bill Douglass, 646-450-3615
Martina Schwarzkopf, Ph.D., 212-845-4292
KEYWORDS: United States North America California Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Research Science